Effect of dapagliflozin on blood pressure, cardiac function, visceral fat in type 2 diabetes mellitus patients with hypertension.

Effect of dapagliflozin on blood pressure, cardiac function, visceral fat in type 2 diabetes mellitus patients with hypertension. - Effect of dapagliflozin on blood pressure, cardiac function, visceral fat in type 2 diabetes mellitus patients with hypertension.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015203

Enrollment

Registered

2014-09-18

Start date

2014-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

dapagliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients T2DM patients with hypertension 1)HbA1C higher than6.5% but lowre than 9% 2)BNP 30-200pg ml 3)acceptable for combination therapy with other anti hyperglycemic agents 4)Blood Pressure higher than 130 and or higher than 85mmHg with anti hypertension agents 5)acceptable for therapy with lipid lowering drug and antihyperuricemic drug 6)20-75years 7)serum creatinine lower than 1.5mg dl 8)higher than BMI18.5 9)subjects who can measure by dualscan 10)subjects who give consent document about participation in the clinical study

Exclusion criteria

Exclusion criteria: 1) Patients who are Type I or Secondary diabetic mellitus 2) Patients who are treating with Insulin theraphy at the time of study initiation 3) Patients who are severe infectious disease, perioperative, and severe trauma 4)Patients who are pregnant, lactating, and possibly pregnant women and those planning to become pregnant 5)Patients with myocardial infarction, angina pectoris, cerebral stroke, or cerebral infarction before 3 month 6) patients with Arrhythmia,atrial fibrillation 7) Patients with a history of hypersensitivity to investigational drugs 8) Patients with cancer 9) Patients who receive steroid therapy with inflammatory affection 10) Patients whom doctor judges as ineligible to this study

Design outcomes

Primary

Measure	Time frame
Change of serum ANP/BNP value comparing with baseline.	—

Secondary

Measure	Time frame
change of fat area in the abdominal cavity comparing with baseline change of HbA1c comparing with baseline change of autonomic nerve function (heart rate variability, QT interval on electrocardiogram) change of fluctuation of blood pressure in day physical measurement(weight, waist circumference) echocardiogram blood test (blood glucose, HbA1c, uric acid, insulin, 1.5AG, total ketone body, renin, aldosterone) urinalysis (sodium, potassium, glucose, creatinine, uric acid)	—

Measure

Time frame

change of fat area in the abdominal cavity comparing with baseline change of HbA1c comparing with baseline change of autonomic nerve function (heart rate variability, QT interval on electrocardiogram) change of fluctuation of blood pressure in day physical measurement(weight, waist circumference) echocardiogram blood test (blood glucose, HbA1c, uric acid, insulin, 1.5AG, total ketone body, renin, aldosterone) urinalysis (sodium, potassium, glucose, creatinine, uric acid)

—

Countries

Japan

Contacts

Public ContactIzuru Masuda

Takeda Hospital Medical Examination Center

imasuda@kuhp.kyoto-u.ac.jp075-365-0825

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026